OneSource Specialty Pharma's Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- OneSource Specialty Pharma Ltd reported a 13.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.9%.
- Its expenses for the quarter were up by 11.7% QoQ and 0.8% YoY.
- The net profit decreased 5615.8% QoQ and decreased 124.9% YoY.
- The earnings per share (EPS) of OneSource Specialty Pharma Ltd stood at 0.91 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 378.80 | 332.54 | 338.45 | 13.9% | 11.9% |
Total Expenses | 373.06 | 334.07 | 370.08 | 11.7% | 0.8% |
Profit Before Tax | 5.74 | -4.40 | -37.45 | -230.5% | -115.3% |
Tax | -4.74 | -4.21 | 4.63 | 12.6% | -202.4% |
Profit After Tax | 10.48 | -0.19 | -42.08 | -5615.8% | -124.9% |
Earnings Per Share | 0.91 | -0.02 | -3.89 | -4650.0% | -123.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
OneSource Specialty Pharma Ltd is a company operating in the pharmaceutical industry, specializing in the development and distribution of specialty pharmaceutical products. The company is engaged in providing innovative solutions to address unmet medical needs. As a key player in the pharmaceutical sector, OneSource focuses on a diverse portfolio of pharmaceutical products that cater to various therapeutic areas. At present, specific details about recent major developments or new product launches are not available.
Revenue
For the second quarter of the fiscal year 2026 (Q2FY26), OneSource Specialty Pharma Ltd reported total income of ₹378.80 crores. This marks a significant increase of 13.9% compared to the first quarter of FY26, where the total income was ₹332.54 crores. Year-over-year, the total income rose by 11.9% from ₹338.45 crores reported in Q2FY25. These figures indicate a positive trend in revenue generation for the company over both the quarter and year.
Profitability
In Q2FY26, the company achieved a profit before tax (PBT) of ₹5.74 crores, contrasting with a loss of ₹4.40 crores in Q1FY26 and a significant loss of ₹37.45 crores in Q2FY25. The quarter-over-quarter change in PBT is an impressive 230.5%, while the year-over-year change stands at 115.3%. After accounting for taxes, the profit after tax (PAT) for Q2FY26 was ₹10.48 crores, which is a substantial improvement from a loss of ₹0.19 crores in the previous quarter and a loss of ₹42.08 crores in the same quarter last year. The changes in PAT are reflected in the earnings per share (EPS), which increased to ₹0.91 from a negative ₹0.02 in the last quarter and negative ₹3.89 in the previous year.
Operating Metrics
The total expenses for OneSource Specialty Pharma Ltd in Q2FY26 were ₹373.06 crores, representing an 11.7% increase from the previous quarter's ₹334.07 crores and a slight year-over-year increase of 0.8% from ₹370.08 crores in Q2FY25. The company's tax expenses also showed a 12.6% increase quarter-over-quarter, with a significant year-over-year shift from a tax expense of ₹4.63 crores in Q2FY25 to a tax benefit of ₹4.74 crores in Q2FY26. The notable changes in expenses and tax implications reflect the operational adjustments and financial strategies employed by the company during this period.